Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bimekizumab in moderate to severe chronic plaque psoriasis
2016-003426-16Phase 3Completed
- Sponsor
- UCB
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Bimekizumab with Placebo (2 arms). Primary endpoint: PASI90 response at Week 16. Started Dec 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2016-003426-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003426-16.